Fresenius Medical Care AG & Co. (Pref) (ETR:FME) has been assigned a €95.40 ($112.24) price target by equities researchers at J P Morgan Chase & Co in a research note issued to investors on Friday. The firm currently has a “buy” rating on the stock.

A number of other research analysts have also recently commented on the stock. Deutsche Bank AG set a €83.00 ($97.65) target price on shares of Fresenius Medical Care AG & Co. (Pref) and gave the company a “neutral” rating in a research report on Friday. Goldman Sachs Group Inc set a €97.00 ($114.12) target price on shares of Fresenius Medical Care AG & Co. (Pref) and gave the company a “buy” rating in a research report on Friday, September 29th. Berenberg Bank set a €95.60 ($112.47) target price on shares of Fresenius Medical Care AG & Co. (Pref) and gave the company a “buy” rating in a research report on Tuesday, September 19th. Morgan Stanley set a €90.00 ($105.88) target price on shares of Fresenius Medical Care AG & Co. (Pref) and gave the company a “buy” rating in a research report on Friday, September 15th. Finally, Citigroup Inc. set a €92.00 ($108.24) target price on shares of Fresenius Medical Care AG & Co. (Pref) and gave the company a “buy” rating in a research report on Tuesday, August 8th. One investment analyst has rated the stock with a sell rating, nine have given a hold rating and ten have assigned a buy rating to the company. The stock currently has an average rating of “Hold” and an average price target of €88.35 ($103.94).

Fresenius Medical Care AG & Co. (FME) traded up 0.559% on Friday, reaching €82.949. 392 shares of the company traded hands. Fresenius Medical Care AG & Co. has a 1-year low of €70.82 and a 1-year high of €89.07. The stock has a market capitalization of €25.45 billion and a price-to-earnings ratio of 21.390. The stock has a 50 day moving average of €81.54 and a 200-day moving average of €82.22.

ILLEGAL ACTIVITY WARNING: “Fresenius Medical Care AG & Co. (Pref) (FME) PT Set at €95.40 by J P Morgan Chase & Co” was first posted by American Banking News and is the property of of American Banking News. If you are viewing this piece of content on another domain, it was illegally copied and republished in violation of US & international copyright laws. The original version of this piece of content can be viewed at https://www.americanbankingnews.com/2017/10/21/fresenius-medical-care-ag-95-40-by-j-p-morgan-chase-co.html.

Fresenius Medical Care AG & Co. (Pref) Company Profile

Fresenius Medical Care AG & Co KGaA, a kidney dialysis company, provides dialysis care and related services, and other health care services. It offers dialysis treatment, and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized ESRD patients and for patients suffering from acute kidney failure.

Analyst Recommendations for Fresenius Medical Care AG & Co. (Pref) (ETR:FME)

Receive News & Ratings for Fresenius Medical Care AG & Co. (Pref) Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fresenius Medical Care AG & Co. (Pref) and related companies with MarketBeat.com's FREE daily email newsletter.